# A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

> **NCT06429800** · PHASE1 · WITHDRAWN · sponsor: **Atara Biotherapeutics**

## Conditions studied

- Lupus Nephritis
- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** ATA3219

## Key facts

- **NCT ID:** NCT06429800
- **Lead sponsor:** Atara Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-04-16
- **Primary completion:** 2025-04-16
- **Final completion:** 2025-04-16
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Financial
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06429800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06429800, "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06429800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*